These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15032783)

  • 1. Design and analysis of group sequential clinical trials with multiple primary endpoints.
    Kosorok MR; Yuanjun S; DeMets DL
    Biometrics; 2004 Mar; 60(1):134-45. PubMed ID: 15032783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
    J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
    Gullestad L; Wikstrand J; Deedwania P; Hjalmarson A; Egstrup K; Elkayam U; Gottlieb S; Rashkow A; Wedel H; Bermann G; Kjekshus J;
    J Am Coll Cardiol; 2005 Jan; 45(2):252-9. PubMed ID: 15653024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.
    Jost A; Rauch B; Hochadel M; Winkler R; Schneider S; Jacobs M; Kilkowski C; Kilkowski A; Lorenz H; Muth K; Zugck C; Remppis A; Haass M; Senges J;
    Eur Heart J; 2005 Dec; 26(24):2689-97. PubMed ID: 16183697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating co-primary endpoints collectively in clinical trials.
    Li QH
    Biom J; 2009 Feb; 51(1):137-45. PubMed ID: 19219905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical testing of multiple endpoints in group-sequential trials.
    Glimm E; Maurer W; Bretz F
    Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
    Eickhoff JC
    Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of heart failure with a preserved ejection fraction.
    Das A; Abraham S; Deswal A
    Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
    Quan H; Luo X; Capizzi T
    Stat Med; 2005 Jul; 24(14):2151-70. PubMed ID: 15909290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gatekeeping testing via adaptive alpha allocation.
    Li JD; Mehrotra DV
    Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
    Kelly PJ; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.